Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment

Dow Jones01-13

By Elias Schisgall

Nuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations.

Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year.

The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter.

Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch.

Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia.

The company also said it received a $25 million milestone payment from Nippon Kayaku during the fourth quarter.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 12, 2026 11:26 ET (16:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603542831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603542831","market":"fut","top_or_hot":-1,"title":"Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations. \n</p>\n<p>\n  Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year. \n</p>\n<p>\n  The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter. \n</p>\n<p>\n  Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch. \n</p>\n<p>\n  Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia. \n</p>\n<p>\n  The company also said it received a $25 million milestone payment from <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> during the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:26 ET (16:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 00:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations. \n</p>\n<p>\n  Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year. \n</p>\n<p>\n  The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter. \n</p>\n<p>\n  Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch. \n</p>\n<p>\n  Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia. \n</p>\n<p>\n  The company also said it received a $25 million milestone payment from <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> during the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:26 ET (16:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603542831","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603542831","pubTimestamp":1768235160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations.Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year.The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter.Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch.Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia.The company also said it received a $25 million milestone pay","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"肺癌治疗销售指引令人失望后，Nuvation Bio股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\nNuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations. \n\n\n  Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year. \n\n\n  The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter. \n\n\n  Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch. \n\n\n  Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia. \n\n\n  The company also said it received a $25 million milestone payment from Nippon Kayaku during the fourth quarter. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 11:26 ET (16:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603542831","isCrawlerRequest":true}